ClinConnect ClinConnect Logo
Search / Trial NCT00000126

Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)

Launched by NATIONAL EYE INSTITUTE (NEI) · Sep 23, 1999

Trial Information

Current as of May 09, 2025

Unknown status

Keywords

Non Arteritic Ischemic Optic Neuropathy

ClinConnect Summary

NAION is the most common cause of acute optic nerve disease in the elderly, causing permanent and severe visual loss. No proven treatment currently exists to reverse or arrest this loss. There is no accepted method for the prevention or reduction of the likelihood of second eye involvement. NAION strikes both eyes in as many as 40 percent of affected patients (Beri et al. 1987), with a 2-year risk of about 25 percent (Steven Feldon, personal communication to SEK).

IONDT compared optic nerve decompression surgery (ONDS), which was becoming a widely used treatment for NAION, with careful fol...

Gender

ALL

Eligibility criteria

  • All living patients from the 420 patients originally enrolled in the IONDT have been asked to participate in the IONDT Followup Study. No new patients are being recruited.

About National Eye Institute (Nei)

The National Eye Institute (NEI), part of the U.S. National Institutes of Health (NIH), is dedicated to conducting and supporting innovative research to understand, prevent, and treat eye diseases and vision disorders. As a leading sponsor of clinical trials, NEI aims to advance knowledge in ocular health through rigorous scientific inquiry and collaboration with researchers, healthcare professionals, and institutions. By fostering the development of new therapies and technologies, NEI plays a pivotal role in enhancing the quality of life for individuals affected by visual impairments and eye conditions.

Locations

Rochester, Minnesota, United States

Los Angeles, California, United States

Los Angeles, California, United States

San Francisco, California, United States

Gainesville, Florida, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

Lexington, Kentucky, United States

Baltimore, Maryland, United States

Ann Arbor, Michigan, United States

East Lansing, Michigan, United States

Royal Oak, Michigan, United States

Columbia, Missouri, United States

St. Louis, Missouri, United States

Syracuse, New York, United States

Charlotte, North Carolina, United States

Cleveland, Ohio, United States

Pittsburgh, Pennsylvania, United States

Columbia, South Carolina, United States

Houston, Texas, United States

Salt Lake City, Utah, United States

Charlottesville, Virginia, United States

Richmond, Virginia, United States

Morgantown, West Virginia, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials